Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Spyryx Biosciences
15 TW Alexander Drive
Research Triangle Park, NC 27709
http://www.spyryxbio.com/

Spyryx Biosciences is developing inhaled therapeutics designed to restore a natural mechanism for maintaining proper airway liquid volumes in the lung. The Company's development efforts are based on recent discoveries in the laboratory of Dr. Robert Tarran at UNC-Chapel Hill, who has demonstrated the connection between a regulatory protein in the lung, called SPLUNC1, and dysregulation of sodium absorption via the epithelial sodium channel (ENaC). The Company's products have been created to mimic the ENaC inhibitory effect of SPLUNC1, but with significantly enhanced potency and drug-like properties. Spyryx is currently in lead selection and expects to proceed rapidly to pre-IND activities for cystic fibrosis, their lead indication.

Key Contact
Name
John Taylor
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
05/07/15 $18,000,000 Series A 5AM Ventures
Canaan Partners
Hatteras Venture Partners
undisclosed